Thiazolidinediones: A novel class of drugs for the prevention of diabetic nephropathy?

F. Zheng; Y. Guan

doi:10.1038/sj.ki.5002557

Thiazolidinediones: A novel class of drugs for the prevention of diabetic nephropathy?

F. Zheng
, Y. Guan^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

29 Scopus citations

Abstract

Diabetic nephropathy is the leading cause of end-stage renal disease. Novel preventive measures for diabetic renal complications are urgently needed. Miyazaki et al. report that rosiglitazone, a thiazolidinedione insulin sensitizer and a potent peroxisome proliferator-activated receptor γ agonist, not only effectively improves glycemic control but also halts progression of albuminuria in type 2 diabetic patients with early-stage diabetic nephropathy. These findings could offer a new prevention of diabetic nephropathy in insulin-resistant diabetic patients.

Original language	English
Pages (from-to)	1301-1303
Number of pages	3
Journal	Kidney International
Volume	72
Issue number	11
DOIs	https://doi.org/10.1038/sj.ki.5002557
State	Published - Dec 2007
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.ki.5002557

Cite this

@article{cd2c9d7d4ce54a68a05041746fd78ab2,

title = "Thiazolidinediones: A novel class of drugs for the prevention of diabetic nephropathy?",

abstract = "Diabetic nephropathy is the leading cause of end-stage renal disease. Novel preventive measures for diabetic renal complications are urgently needed. Miyazaki et al. report that rosiglitazone, a thiazolidinedione insulin sensitizer and a potent peroxisome proliferator-activated receptor γ agonist, not only effectively improves glycemic control but also halts progression of albuminuria in type 2 diabetic patients with early-stage diabetic nephropathy. These findings could offer a new prevention of diabetic nephropathy in insulin-resistant diabetic patients.",

author = "F. Zheng and Y. Guan",

year = "2007",

month = dec,

doi = "10.1038/sj.ki.5002557",

language = "英语",

volume = "72",

pages = "1301--1303",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Elsevier B.V.",

number = "11",

}

TY - JOUR

T1 - Thiazolidinediones

T2 - A novel class of drugs for the prevention of diabetic nephropathy?

AU - Zheng, F.

AU - Guan, Y.

PY - 2007/12

Y1 - 2007/12

N2 - Diabetic nephropathy is the leading cause of end-stage renal disease. Novel preventive measures for diabetic renal complications are urgently needed. Miyazaki et al. report that rosiglitazone, a thiazolidinedione insulin sensitizer and a potent peroxisome proliferator-activated receptor γ agonist, not only effectively improves glycemic control but also halts progression of albuminuria in type 2 diabetic patients with early-stage diabetic nephropathy. These findings could offer a new prevention of diabetic nephropathy in insulin-resistant diabetic patients.

AB - Diabetic nephropathy is the leading cause of end-stage renal disease. Novel preventive measures for diabetic renal complications are urgently needed. Miyazaki et al. report that rosiglitazone, a thiazolidinedione insulin sensitizer and a potent peroxisome proliferator-activated receptor γ agonist, not only effectively improves glycemic control but also halts progression of albuminuria in type 2 diabetic patients with early-stage diabetic nephropathy. These findings could offer a new prevention of diabetic nephropathy in insulin-resistant diabetic patients.

UR - https://www.scopus.com/pages/publications/36248983781

U2 - 10.1038/sj.ki.5002557

DO - 10.1038/sj.ki.5002557

M3 - 评论/辩论

C2 - 18004308

AN - SCOPUS:36248983781

SN - 0085-2538

VL - 72

SP - 1301

EP - 1303

JO - Kidney International

JF - Kidney International

IS - 11

ER -

Thiazolidinediones: A novel class of drugs for the prevention of diabetic nephropathy?

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this